My broad research interest is in the qualitative study of cross-national variation in health and social policies: why do jurisdictions choose different responses to similar policy problems, and what opportunities and challenges do these different policies present for reform?

My current research examines the adoption and reform of drug assessment and reimbursement policies, with a focus on the use of cost-effectiveness analysis programs for pharmaceuticals since the early 1990s and the expansion of public and patient involvement since the early 2000s. My 2015 University of Toronto Press book compares the development (or non-development) of nation-wide pharmaceutical insurance in Canada, the UK, and Australia, in order to explain why Canada is the only mature welfare state that does not include broad public coverage for drugs. Previously, I have studied the use of children’s environmental health as a framing strategy for the regulation of toxins in the United States and Canada.

Selected publications

Katherine Boothe. 2019. “Getting to the table”: Changing ideas about public and patient involvement in Canadian drug assessment.” Journal of Health Politics, Policy and Law 44 (4): 631-663.

Katherine Boothe. 2018. “Pharmaceutical policy reform in Canada: lessons from history.” Health Economics, Policy and Law. 13(3-4): 299-322.

Steve Morgan and Katherine Boothe. 2016. “Universal prescription drug coverage in Canada: long-promised yet undelivered.” Joint Issue of Healthcare Management Forum (Canada) and Health Services Management Research (Europe) 29(6):247-254.

Katherine Boothe. 2016. “Evaluating the cost-effectiveness of pharmaceuticals in Canada.” Health Reform Observer. 4(1): 1-20.

Katherine Boothe. 2015. Ideas and the pace of change: national pharmaceutical insurance in Canada, Australia and the United Kingdom. Toronto: University of Toronto Press.

Katherine Boothe. 2013. “Ideas and the limits on program expansion: the failure of nation-wide pharmacare in Canada, 1944-2002.” Canadian Journal of Political Science 46(2): 419-453.

Katherine Boothe. 2012. “How the pace of change affects the scope of reform: pharmaceutical insurance in Canada, Australia and the UK.” Journal of Health Politics, Policy and Law 37(5): 779-814.

Steve Morgan and Katherine Boothe. 2010. “Prescription drug subsidies in Australia and New Zealand.” Australian Prescriber, 33: 2-4. (peer-reviewed commentary)

Katherine Boothe and Kathryn Harrison. 2009. “The Influence of Institutions on Issues Definition: Children’s Environmental Health Policy in the United States and Canada.” Journal of Comparative Policy Analysis, 11(3): 287-307.

Steve Morgan, Jae Kennedy, Katherine Boothe, Meghan McMahon, Diane Watson, Elizabeth Roughead. 2009. “Toward an Understanding of High Performance Pharmaceutical Policy Systems: A “Triple-A” Framework and Example Analysis.” The Open Health Services and Policy Journal, 2:1-9.

If you would like a copy of the published version of any of these papers, please email me

Selected papers under review or in progress

Katherine Boothe. Pharmaceutical policy reform in Canada: lessons from history. Accepted for publication in final form Health Economics, Policy and Law, September 2017.

Katherine Boothe. Who Decides Who Gets What? Changing Ideas About Public and Patient Involvement in Drug Assessment. Article under review, October 2017.

If you are looking for a paper you do not see here, please email me